Full Breakdown
Archimed’s $1.1 Billion Take-Private of Esperion Therapeutics
5/2/2026, 4:03:00 AM
Recent Acquisitions and Product Portfolio
Esperion Therapeutics, a Michigan drugmaker, acquired Corstasis Therapeutics in March 2026, adding Enbumyst, a bumetanide nasal spray approved in September 2025 for edema. Its core cholesterol drugs, Nexletol and Nexlizet, generated $159.6 million in 2025 product sales; total 2025 revenue was $403.1 million, with a net loss of $22.7 million and cash of $167.9 million.
Deal Terms and Financial Metrics
Archimed will pay $3.16 cash per share, a 58 % premium to the April 30 price, valuing Esperion at about $1.1 billion. With roughly 245 million shares outstanding, the deal includes up to $100 million in contingent value rights: $40 million if cholesterol-drug sales exceed $350 million in 2027, and $60 million if Enbumyst sales reach $160 million before Dec 31 2030. The board approved unanimously; closing is expected in Q3 2026 pending antitrust clearance.
Strategic Rationale and Expected Impact
The acquisition gives Archimed a platform in the cardiometabolic market and provides Esperion with immediate cash value for shareholders. Archimed’s backing is intended to accelerate Esperion’s “Vision 2040” strategy, which aims to expand treatment options for patients at risk of heart disease. If the sales milestones are met, the CVRs could deliver additional cash flow, enhancing the long-term financial upside beyond the upfront premium.
Official Statements & Responses
Esperion CEO Sheldon Koenig said Archimed’s support positions the company to advance its Vision 2040 strategy and tackle the global cardiometabolic disease burden. Archimed partner Justin Bateman noted Esperion’s strong foundation in cardiovascular and primary-care markets. The board’s unanimous vote signals confidence that the deal will create shareholder value and take Esperion private, ending its Nasdaq listing.
Criticism & Opposition
Cantor analyst Kristen Kluska argued that the deal appears low-priced given Esperion’s projected U.S. peak sales of about $1.5 billion, suggesting that market-penetration assumptions may be overly optimistic.
Conflicting Views on Valuation
Buy-side analysts such as Citizens, Needham and Piper Sandler have issued buy ratings with price targets ranging from $5 to $9 per share (average $6.33), reflecting optimism about future growth. By contrast, Kluska’s assessment points to a valuation gap, indicating divergent expectations among market participants.
Verbatim Quotes
- “With ARCHIMED’s support, we believe Esperion will be well positioned to advance our Vision 2040 strategy and continue addressing the global burden of cardiometabolic disease,” — Sheldon Koenig, CEO, Esperion Therapeutics
- “attractive and immediate upfront value” — Sheldon Koenig, CEO, Esperion Therapeutics
- “strong foundation” — Justin Bateman, Partner, Archimed
What’s Next
Closing is targeted for Q3 2026 pending antitrust clearance. After the transaction, Esperion will become private and its Nasdaq ticker will be retired. The CVR milestones will be monitored through 2027-2030, and Archimed may pursue further product development or strategic acquisitions to deepen the cardiometabolic portfolio.
